Immatics NV (IMTX) Stock Analysis

Immatics NV (IMTX) is a publicly traded company in the HEALTHCARE sector. It trades at $10.04, carries a market capitalization of $1.57B. This page summarizes the public market data, fundamentals, and frequently asked questions for IMTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Immatics NV currently has a Bullish sentiment score of 0.35.

About Immatics NV

Immatics NV is a pioneering clinical-stage biopharmaceutical firm based in Tübingen, Germany, focused on advancing T-cell receptor (TCR) based immunotherapies for cancer treatment. Harnessing its proprietary platform, the company identifies and targets unique cancer-specific antigens, which may significantly improve immune responses against tumors. With a robust pipeline of innovative therapeutics, Immatics is strategically positioned to meet critical unmet needs in oncology, representing a c...

GNG Research Analysis

GNG Research scores Immatics NV (IMTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IMTX.

Frequently Asked Questions

Does IMTX pay dividends?

Immatics NV (IMTX) does not currently pay a regular dividend.

What is IMTX's market cap?

Immatics NV (IMTX) has a market capitalization of $1.57B with a current stock price of $10.04.